191 related articles for article (PubMed ID: 21647781)
1. Primary peritoneal serous papillary carcinoma: a clinical and pathological study.
Liu Q; Lin JX; Shi QL; Wu B; Ma HH; Sun GQ
Pathol Oncol Res; 2011 Sep; 17(3):713-9. PubMed ID: 21647781
[TBL] [Abstract][Full Text] [Related]
2. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
3. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
4. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
5. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses.
Zhang C; Li XP; Cui H; Shen DH; Wei LH
J Zhejiang Univ Sci B; 2008 Jun; 9(6):435-40. PubMed ID: 18543395
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Bodurka DC; Levenback C; Wolf JK; Gano J; Wharton JT; Kavanagh JJ; Gershenson DM
J Clin Oncol; 2003 Jan; 21(2):291-7. PubMed ID: 12525521
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
Barnetson RJ; Burnett RA; Downie I; Harper CM; Roberts F
Am J Clin Pathol; 2006 Jan; 125(1):67-76. PubMed ID: 16482993
[TBL] [Abstract][Full Text] [Related]
8. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma].
Gong HL; Wang CB; Zhang GJ; Li CF; Yang XY; Hou HL; Zhang XB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):463-5. PubMed ID: 19567094
[TBL] [Abstract][Full Text] [Related]
10. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Int J Gynecol Cancer; 2001; 11(5):403-8. PubMed ID: 11737473
[TBL] [Abstract][Full Text] [Related]
11. [Cytopathological characterization of ascites for the diagnosis of serous ovarian carcinoma].
Chang YH; Zou BQ; Cai Y; Yang SD; Zhang Y; Liang JB; Li C
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):424-432. PubMed ID: 37188628
[No Abstract] [Full Text] [Related]
12. Primary peritoneal serous papillary carcinoma: a case series.
Blontzos N; Vafias E; Vorgias G; Kalinoglou N; Iavazzo C
Arch Gynecol Obstet; 2019 Oct; 300(4):1023-1028. PubMed ID: 31486887
[TBL] [Abstract][Full Text] [Related]
13. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
15. Nuclear receptor DAX-1 in human common epithelial ovarian carcinoma: an independent prognostic factor of clinical outcome.
Abd-Elaziz M; Akahira J; Moriya T; Suzuki T; Yaegashi N; Sasano H
Cancer Sci; 2003 Nov; 94(11):980-5. PubMed ID: 14611675
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
18. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study.
Zhou J; Iwasa Y; Konishi I; Kan N; Kannagi R; Kobashi Y; Kim YC; Yamabe H
Cancer; 1995 Aug; 76(3):429-36. PubMed ID: 8625124
[TBL] [Abstract][Full Text] [Related]
19. Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics.
Iavazzo C; Vorgias G; Katsoulis M; Kalinoglou N; Dertimas V; Akrivos T
Arch Gynecol Obstet; 2008 Jul; 278(1):53-6. PubMed ID: 18488238
[TBL] [Abstract][Full Text] [Related]
20. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
